Publications database

Hepatitis C virus (HCV) infection is the most common infectious disease in people who inject drugs, among whom it is usually transmitted through the sharing of syringes and other drug use equipment...

Partnership is a guiding principle for the EMCDDA as it works to increase its understanding of the external dimension of the drug phenomenon and its implications for public health and security in...

This report is part of the EMCDDA-IPA5 project ‘Further preparation of the IPA beneficiaries for their participation with the European Monitoring Centre for Drugs and Drug Addiction’ funded by the European Commission...

This report presents the key activities performed by the EMCDDA and Europol in 2017 and the results of the implementation of Council Decision 2005/387/JHA on the information exchange, risk assessment and control...

This evidence-based guidance aims to support the planning and implementation of effective programmes to prevent and control the transmission of infectious diseases in prison settings in the European region. It focuses on...

This evidence-based guidance aims to support the planning and implementation of effective programmes to prevent and control the transmission of infectious diseases in prison settings in the European region. It focuses on...

Compared with the general public, people in prisons have a higher prevalence of infection with blood-borne viruses (BBVs) such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus...

This publication presents the data and findings of the risk assessment on methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018...

This publication presents the data and findings of the risk assessment on methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018...

This publication presents the data and findings of the risk assessment on N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. In March 2018, at...